<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857779</url>
  </required_header>
  <id_info>
    <org_study_id>AF-H-01</org_study_id>
    <nct_id>NCT00857779</nct_id>
  </id_info>
  <brief_title>Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients</brief_title>
  <official_title>A Multicentre Randomised Phase II Clinical Trial to Demonstrate Equivalent Pharmacodynamic Efficacy and Tolerability of Two Updosing Schedules for ALK-Flex SQ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking
      factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IgE-blocking factor</measure>
    <time_frame>start of treatment and 1 week after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of two different updosing schedules</measure>
    <time_frame>throughout treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">473</enrollment>
  <condition>Rhinitis</condition>
  <condition>Conjunctivitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous immunotherapy using a slow updosing schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous immunotherapy using a fast updosing schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>subcutaneous immunotherapy</intervention_name>
    <description>7 injections</description>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <arm_group_label>subcutaneous injections</arm_group_label>
    <other_name>AVANZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical history of grass pollen induced allergic rhinoconjunctivitis of two years
             or more requiring treatment during the grass pollen season

          -  Lack of adequate relief with symptomatic medication during the previous grass pollen
             season

          -  Positive Skin Prick Test (SPT) response to Phleum pratense (wheal diameter &gt;= 3mm)
             currently performed or not older than 60 days before screening

        Exclusion Criteria:

          -  FEV1 &lt; 70% of predicted value at screening

          -  Bronchial asthma corresponding to GINA step 3 or more, even if controlled

          -  History of asthma exacerbation or emergency visit or admission for asthma in the
             previous 12 months

          -  Previous treatment by immunotherapy with grass pollen allergen or any other allergen
             within the previous 5 years

          -  Exclusion criteria in accordance with contraindications in the SPC of ALK-Flex SQ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Jung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private practice, Erfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergists` practice Dr. Kirsten Jung</name>
      <address>
        <city>Erfurt</city>
        <state>Thueringen</state>
        <zip>D-99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy. 2012 May;67(5):630-7. doi: 10.1111/j.1398-9995.2012.02801.x. Epub 2012 Mar 3.</citation>
    <PMID>22385366</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergen immunotherapy</keyword>
  <keyword>allergy to grass pollen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

